Phase 2 N=62 Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)
Ovarian Cancer
Primary: PFS — 29.8 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=963 Cancer Loyalty Card Study
Ovarian Neoplasms
Primary: Purchase Behaviours (Purchase of Items) — 3.2; 2.0; 5.9; 4.3 number of items purchased — p=<0.001
N/A N=232 Predictors of Ovarian Insufficiency in Young Breast Cancer Patients
Breast Cancer · Ovarian Insufficiency · Ovarian Failure
Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants
N/A N=22 Sentinel Node Detection in Clinical Early Stage Ovarian Cancer
Ovarian Cancer · Sentinel Node
Primary: Number of Patients (%) in Which Sentinel Node(s) Are Detected After Injection of Blue Dye and Tracer in the Ovarian Ligaments. — 21 participants
Phase 2 N=58 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Overall Survival — 32 months
Phase 2 N=55 Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
Ovarian Neoplasm · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Clinical Response Rate. — 0; 19; 21; 60 percentage of participants
Phase 3 N=740 Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
Breast Cancer
Primary: Disease-free Survival — 64; 71; 70 percentage of participants
Phase 2 N=32 Neoadjuvant Therapy for Ovarian Cancer
Epithelial Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events
Phase 2 N=28 Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants
Phase 3 N=249 Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer
Breast Cancer
Primary: Overall Survival — 2.14; 2.00 years
Phase 2 N=132 TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary
Ovarian Cancer
Primary: Twelve-month Progression-free Survival (PFS) Rate in Participants — 65.7 percentage of participants
Phase 3 N=1,301 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…
N/A N=221 Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4
Ovarian Tumor · Ovarian Cancer
Primary: Tumor Marker CA125 — 189; 4 U/mL — p=<0.001
Phase 2 N=26 Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
Ovarian Cancer
Primary: Patients' Overall 90-Day Clinical Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) — 8; 18 Participants
Phase 2 N=50 Gemcitabine in Ovarian Cancer
Ovarian Cancer
Primary: Best Overall Tumor Response — 6; 25; 10; 5 participants
Phase 1 N=15 Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2
Phase 2 N=148 A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Progression-free Survival — 2.9; 5.3 months — p=0.019
Phase 2 N=85 Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
Ovarian Cancer
Primary: 2-year Progression-free Survival — 40; 40 percentage of participants
Phase 2 N=246 Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
Ovarian Neoplasms
Primary: Progression-free Survival (PFS), Based on Radiological or Pathologic Assessment — 386; 478 Days — p=0.655
Phase 2 N=103 A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Percentage of Participants With Complete Response and Partial Response (Objective Response Rate) — 7.5; 0; 3.1 percentage of participants
Phase 2 N=1 Salvage Ovarian FANG™ Vaccine + Carboplatinum
Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Time to Progression (TTP)
Phase 2 N=64 Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer
Ovarian Carcinoma
Primary: Median Proportion Cells That Are Apoptotic in Epithelial Ovarian Tissue — .093; .115 proportion of total cells
Phase 1 N=7 Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer
Ovarian Cancer
Primary: Number of Patients With Dose-limiting Toxicities (DLTs) — 0; 0 Participants
Phase 2 N=56 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
Brenner Tumor · Fallopian Tube Cancer · Ovarian Clear Cell Cystadenocarcinoma
Primary: Pathologic Complete Response Rates — 8 participants
N/A N=2,331 Connecting Families to Overcome Ovarian Cancer
Ovarian Cancer
Primary: Number of Survivors Using Website Access Code — 147; 202 Participants
Phase 2 N=59 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Consolidation Progression-Free Survival — 13.3; 18.9 months
Phase 2 N=40 Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer
Ovarian Neoplasms
Primary: Objective Response (Complete Partial, Stable and Progression) — 1; 8; 10; 20 Participants
Phase 2 N=36 A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
Peritoneal Cancer · Ovarian Cancer · Neoplasms, Ovarian
Primary: Best Biochemical Response (Cancer Antigen [CA-125]) — 6; 25; 56; 3 percentage of participants
Phase 2 N=8 Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer
Ovarian Cancer · Primary Peritoneal Cancer
Primary: The Cystostatic, Anti-tumor Activity of the Combination of Gleevec and Gemzar Via Progression-free Survival for at Least Six Months in Patients With Recurrent or…
Phase 2 N=24 Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Progression-free Survival at 6 Months — 13.6 percentage of participants